1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Algeria Pharmaceuticals and Healthcare Report Q1 2016

Algeria Pharmaceuticals and Healthcare Report Q1 2016

  • November 2015
  • -
  • Business Monitor International
  • -
  • 90 pages

Includes 3 FREE quarterly updates

BMI View: While the effects of the global oil price slump will slowdown Algeria's public and privatespending growth rates over a multi-quarter horizon, the government will keep the modernisation ofhealthcare facilities and the expansion of drug manufacturing capacities among its priorities. Indeed, whilewe forecast a sharp decline in pharmaceutical imports in 2015, we expect import growth to pick up from2016 onwards, albeit at a slower pace than in previous years, reflecting the expansion of localmanufacturing capabilities as well as import restrictions.

However, the growing demand forpharmaceuticals will not be sufficiently covered by local production, with the import of high-end productsto grow as consumer affordability levels increase in line with economic improvement.Risk/Reward IndexIn Q116, we have revised Algeria's Pharmaceutical Risk/Reward Index (RRI) score upwards to 48.1 (out of100) from 46.4 previously. This is above the regional average of 40.3. The score revision was driven byimproved industry rewards indices and country rewards indices. Algeria is now in tenth place (up oneposition from last quarter) out of 31 countries in the Middle East and Africa region. Algeria's score isboosted by a large pharmaceutical market and a favourable long-term market development, but draggeddown by the country's poor regulatory environment.

Table Of Contents

Algeria Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Algeria 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Algeria 2011-2019) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Algeria 2011-2019) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Algeria 2011-2019) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Algeria 2011-2019) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Algeria 2011-2019) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Algeria 2011-2019) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Algeria 2011-2019) 23
OTC Medicines Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Algeria 2011-2019) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Algeria 2013-2019) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Algeria 2013-2019) 28
Industry Risk Reward Index 29
Middle East and Africa Risk/Reward Index - Q1 2016 29
Algeria Risk/Reward Index 37
Rewards 37
Risks 38
Regulatory Review 39
Latest Regulatory Developments 40
Trade Agreements 42
Intellectual Property Issues 43
Pricing Regime 46
Reimbursement Regime 46
Market Overview 48
Healthcare Sector 49
Research and Developments 51
Clinical Trials 53
Epidemiology 54
Competitive Landscape 57
Research-Based Industry 57
Generic Drugmakers 59
Company Developments 60
Table: Table: Multinational Market Activity 61
Pharmaceutical Distribution 62
Pharmaceutical Retail 63
Company Profile 64
GlaxoSmithKline 64
Groupe Saidal 66
Merck and Co 70
Novartis 72
Pfizer 74
Sanofi 76
Demographic Forecast 79
Table: Population Headline Indicators (Algeria 1990-2025) 80
Table: Key Population Ratios (Algeria 1990-2025) 80
Table: Urban/Rural Population and Life Expectancy (Algeria 1990-2025) 81
Table: Population By Age Group (Algeria 1990-2025) 81
Table: Population By Age Group % (Algeria 1990-2025) 82
Glossary 84
Methodology 86
Pharmaceutical Expenditure Forecast Model 86
Healthcare Expenditure Forecast Model 86
Notes On Methodology 87
Risk/Reward Index Methodology 88
Index Overview 89
Table: Pharmaceutical Risk/Reward Index Indicators 89
Indicator Weightings 90

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.